OptiBiotix health doubles turnover as margins strengthen

OptiBiotix Health has reported a period of strong growth in the first half, with turnover more than doubling year-on-year.

In the six months to 30 June 2025, the life sciences business, which develops compounds to tackle obesity, cardiovascular disease and diabetes, delivered revenues of £557,000, up 102% from £276,000. Gross profit climbed 173% to £303,000, while the group reported a loss for the period of £1.18m  compared to £1.34m in the same period la... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...